Alliance Global Partners initiated coverage of Merus (MRUS) with a Buy rating and $90 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus N.V. Reports Q2 2025 Financial Results
- Merus’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
- Optimistic Buy Rating for Merus Driven by Future Data on Petosemtamab in CRC
- Merus’s Strategic Advances in Biotechnology: Buy Rating Driven by Promising mCRC Data Outlook and Innovative Trial Designs
- Merus reports Q2 EPS ($2.23), consensus ($1.15)